Frankfurt - Delayed Quote EUR
Jazz Pharmaceuticals plc (J7Z.F)
As of 8:05 AM GMT+2. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| No. of Analysts | 16 | 16 | 15 | 16 |
| Avg. Estimate | 3.26 | 3.43 | 14.5 | 17.66 |
| Low Estimate | 2.88 | 3.15 | 13.99 | 14.77 |
| High Estimate | 3.69 | 3.94 | 15.29 | 19.57 |
| Year Ago EPS | 4.31 | 4 | 12.46 | 14.5 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| No. of Analysts | 15 | 15 | 16 | 16 |
| Avg. Estimate | 834.65M | 894.06M | 3.09B | 3.76B |
| Low Estimate | 807.3M | 868.8M | 3.04B | 3.51B |
| High Estimate | 860.5M | 922M | 3.13B | 3.96B |
| Year Ago Sales | 600.89M | 665.52M | 2.36B | 3.09B |
| Sales Growth (year/est) | 38.90% | 34.30% | 30.70% | 21.60% |
Earnings History
| CURRENCY IN USD | 9/30/2020 | 12/31/2020 | 3/31/2021 | 6/30/2021 |
|---|---|---|---|---|
| EPS Est. | 4.08 | 4.2 | 3.71 | 3.43 |
| EPS Actual | 4.31 | 4 | 3.92 | 3.9 |
| Difference | 0.23 | -0.2 | 0.21 | 0.47 |
| Surprise % | 5.60% | -4.80% | 5.70% | 13.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| Current Estimate | 3.26 | 3.43 | 14.5 | 17.66 |
| 7 Days Ago | 3.26 | 3.43 | 14.49 | 17.59 |
| 30 Days Ago | 3.26 | 3.43 | 14.49 | 17.59 |
| 60 Days Ago | 3.36 | 3.74 | 14.55 | 17.9 |
| 90 Days Ago | 3.27 | 3.77 | 14.34 | 17.62 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | J7Z.F | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -24.40% | -- | -- | 3.60% |
| Next Qtr. | -14.20% | -- | -- | 7.90% |
| Current Year | 16.40% | -- | -- | 2.50% |
| Next Year | 21.80% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 19.25% | -- | -- | 11.87% |
| Past 5 Years (per annum) | 12.94% | -- | -- | -- |
Upgrades & Downgrades
| Maintains | RBC Capital: Outperform to Outperform | 10/4/2024 |
| Reiterates | Needham: Buy to Buy | 9/10/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/9/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 8/19/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 8/1/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 8/1/2024 |
Related Tickers
20D0.F Cidara Therapeutics, Inc.
10.20
0.00%
430.F Terns Pharmaceuticals Inc
6.55
-1.50%
0RK.F Exscientia plc
4.6000
-2.13%
38I.F Intellia Therapeutics, Inc.
18.80
-2.67%
J90.F NurExone Biologic Inc.
0.3500
-7.41%
VX1.F Vertex Pharmaceuticals Incorporated
440.55
-0.44%
1VT.F Viking Therapeutics, Inc.
60.78
+2.67%
NRX.V NurExone Biologic Inc.
0.5400
0.00%
XBIO Xenetic Biosciences, Inc.
3.7650
+1.76%
CDTX Cidara Therapeutics, Inc.
11.22
-0.36%